2019年08月 -PART 02-
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med 2019; 200（3）: 336‒347
Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function
Am J Respir Crit Care Med 2019; 200（3）: 348‒358
Etiology and Risk Factors for Mortality in an Adult Community-acquired Pneumonia Cohort in Malawi
Am J Respir Crit Care Med 2019; 200（3）: 359‒369
2019年08月 -PART 01-
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med 2019; 200（2）: 168‒174
The Long Noncoding RNA DNM3OS Is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF-β and Pulmonary Fibrosis
Am J Respir Crit Care Med 2019; 200（2）: 184‒198
The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med 2019; 200（2）: 209‒219
Selected articles from AJRCCM. Copyright 2018 by the American Thoracic Society. All rights reserved. The ideas and opinions expressed in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) or other associated publications do not necessarily reflect those of the American Thoracic Society (ATS). The authors, editors or ATS are not responsible for errors or omissions of articles published in print or online from AJRCCM or other associated ATS publications. Although great care has been taken in compiling the content of this publication, neither ATS or their servants are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising there from. Approved product information should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ATS assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.
The translation is © 2018 American Thoracic Society. American Thoracic Society or Springer Healthcare takes no responsibility for the accuracy of the translation from the published English original and are not liable for any errors that may occur.